CG Oncology (CGON) director sells 1,000 shares at $74.54
Rhea-AI Filing Summary
CG Oncology, Inc. (CGON) director Leonard E. Post reported an option exercise and related share sale. On 2026-08-14 he exercised a fully vested director stock option for 1,000 shares of common stock at an exercise price of $0.60 per share, then sold 1,000 shares of common stock at $74.54 per share in a transaction reported as a sale in the open market or a private transaction. After the exercise, he held 104,077 director stock options directly. The sale was carried out under a Rule 10b5-1 trading plan adopted on March 5, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,000 shares ($74K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
POST LEONARD E
Role
Director
Sold
1,000 shs ($75K)
Approx. gross sale proceeds
$75K
Approx. exercise cost
$600.00
Approx. pre-tax spread
$74K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) F2 | 1,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,000 | $0.60 | $600.00 |
| Sale | Common Stock F1 | 1,000 | $74.54 | $75K |
Holdings After Transaction:
Director Stock Option (right to buy) — 104,077 shares (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
- F2. Fully vested
Key Figures
Options Exercised: 1,000 shares
Exercise Price: $0.60 per share
Shares Sold: 1,000 shares
+3 more
6 metrics
Options Exercised
1,000 shares
Director stock options exercised into common stock on 2026-08-14
Exercise Price
$0.60 per share
Exercise price of director stock option converted on 2026-08-14
Shares Sold
1,000 shares
Common stock sold on 2026-08-14
Sale Price
$74.54 per share
Price for sale of CGON common stock on 2026-08-14
Options Held After Transaction
104,077 shares
Director stock options directly owned after reported option exercise
10b5-1 Plan Adoption Date
March 5, 2026
Rule 10b5-1 trading plan governing the reported sale
Key Terms
Rule 10b5-1 trading plan, Director Stock Option (right to buy), derivative security
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Director Stock Option (right to buy) financial
"security_title: Director Stock Option (right to buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did CGON director Leonard E. Post report on this Form 4?
Leonard E. Post reported exercising 1,000 director stock options at $0.60 and selling 1,000 common shares at $74.54 on 2026-08-14, all held directly as reported in the filing.
Was the CGON insider sale by Leonard E. Post under a Rule 10b5-1 plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Leonard E. Post on March 5, 2026, indicating the transactions followed a pre-established plan.
How many CGON director stock options does Leonard E. Post hold after these transactions?
After the reported option exercise, Leonard E. Post directly held 104,077 director stock options in CG Oncology, Inc., as indicated by the total shares following the derivative transaction field in the Form 4 data.
What types of securities were involved in Leonard E. Post’s CGON Form 4 filing?
The filing involves a Director Stock Option (right to buy), which is a derivative security, and the underlying Common Stock of CG Oncology, Inc., including both the acquisition via exercise and the subsequent sale of shares.
Is Leonard E. Post a director or officer of CG Oncology, Inc. (CGON)?
Leonard E. Post is reported as a director of CG Oncology, Inc. in the Form 4. He is not listed as an officer and is not identified as a ten percent owner in the reported data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
